drugset / Trial / NCT05020860
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Timeline
- Start
- 2023-04-18
- Primary completion
- 2027-08
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 1.5 unknown | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Comparator | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Comparator | Pertuzumab/Trastuzumab/Hyaluronidase-zzxf | Unknown | 600 mg | Subcutaneous |
| Comparator | Pertuzumab/Trastuzumab/Hyaluronidase-zzxf | Unknown | 20000 iu | Subcutaneous |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |